Guang-Yu Yang

Guang-Yu Yang

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
AEAhmed Elshazly
Ahmed Elshazly
JLJiong Li
Jiong Li
GYGuang-Yu Yang
Guang-Yu Yang
SRSenthil Radhakrishnan
Senthil Radhakrishnan
The maintenance of gastrointestinal homeostasis relies on a tightly coordinated interplay between the intestinal epithelium, the immune system, and the commensal microbiome. Disruption of this balance underlies inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, and is characterized by chronic, relapsing mucosal inflammation driven by genetic susceptibility, environmental factors, immune dysregulation, and microbial imbalance. Persistent inflammation promotes repeated cycles of epithelial injury and aberrant repair, creating a permissive environment for dysplasia and the development of colitis-associated cancer, most notably colorectal carcinoma. Recent evidence identifies the anti-apoptotic regulator myeloid cell leukemia-1 (Mcl1) as a critical determinant of epithelial integrity and cellular turnover during mucosal stress. Loss or destabilization of Mcl1 disrupts epithelial homeostasis, amplifies inflammatory signaling, and accelerates tumor initiation, whereas its adaptive upregulation in established malignancy promotes tumor cell survival, metabolic fitness, and therapeutic resistance. Thus, Mcl1 functions as a context-dependent molecular switch via restraining malignant transformation during chronic inflammation while supporting tumor progression once neoplasia is established. This functional duality positions Mcl1 as both a biomarker of disease progression and a therapeutically actionable vulnerability. In this review, we synthesize recent advances elucidating how Mcl1 integrates epithelial cell-fate decisions, immune signaling and tumor evolution across the IBD–cancer continuum. We further support these concepts through integrative analyses of multiple transcriptomic datasets comparing normal colonic mucosa with colorectal tumors, and we discuss emerging pharmacological strategies targeting Mcl1 in colitis-associated cancer.

25 December 2025 in Journal of Histochemistry & Cytochemistry
Verified
Journal Article
Closed access
LSLeyu Sun
Leyu Sun
ATAmy Tang
Amy Tang
JLJie Liao
Jie Liao
GYGuang-Yu Yang
Guang-Yu Yang
Lipid signaling molecules are essential for maintaining intestinal mucosal barrier homeostasis. Over 80% of polyunsaturated fatty acids (PUFAs) are metabolized through the cytochrome P450 epoxygenase (CYP)-soluble epoxide hydrolase (sEH) axis, generating bioactive epoxy and diol fatty acids. However, the expression patterns and functional roles of these enzymes in the intestinal epithelium remain poorly defined. To address this, we used RNAscope in situ hybridization and publicly available single-cell RNA sequencing (scRNAseq) datasets to map the cell-type-specific expression of PUFA-metabolizing enzymes in the small intestine. In humans, we identified three major epithelial expression patterns: (1) stem-cell-dominant (CYP2E1), (2) enterocyte-dominant (CYP1A1), and (3) widespread expression across epithelial subsets for key CYP epoxygenases (CYP2C8, 2C9, 2C18, 2C19, 2J2, 2S1), sEH, and additional CYPs (3A4, 4A11, 4F2, 4F3, 4F8, 4F12). In mice, five distinct expression patterns were found: (1) stem cell and transit-amplifying cells (CYP2E1), (2) transit-amplifying dominant (CYP4F18), (3) transit-amplifying and enterocytes (CYP2C44), (4) enterocyte-dominant (CYP1A1), and (5) broadly expressed across all epithelial clusters (sEH, CYP2B10, 2S1, 2C55, 4F13, 4F16). Furthermore, in a radiation-induced small-bowel injury-regeneration model, we observed dynamic changes in CYP expression patterns. These findings provide the first high-resolution single-cell atlas of CYP–sEH axis enzymes in the intestinal epithelium, offering key insights into their potential roles in epithelial differentiation, injury response, and mucosal barrier integrity. This foundational work enables future studies to define the biological functions and therapeutic relevance of PUFA-derived lipid mediators in intestinal health and disease:

27 April 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
GRGrace Jinfeng Rilee
Grace Jinfeng Rilee
SRSenthil Radhakrishnan
Senthil Radhakrishnan
GYGuang-Yu Yang
Guang-Yu Yang
JLJiong Li
Jiong Li
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease, are chronic inflammatory disorders of the gastrointestinal tract associated with epithelial barrier dysfunction, dysregulated immune responses, and an increased risk of cancer. Persistent inflammation is a key driver of IBD-associated tumorigenesis, yet the transcriptional regulators linking inflammatory signaling to epithelial transformation remain incompletely defined. FOSL1 (FOS-like antigen 1), a member of the activator protein-1 (AP-1) transcription factor family, has emerged as a critical mediator at the intersection of inflammation, epithelial homeostasis, and cancer progression. FOSL1 is induced by pro-inflammatory pathways commonly activated in IBD, including MAPK/ERK, NF-κB, and cytokine signaling, and regulates gene programs involved in cell proliferation, migration, barrier integrity, immune modulation, and survival. Accumulating evidence demonstrates that FOSL1 expression is elevated in inflamed intestinal mucosa and in IBD-associated malignancies, where it contributes to epithelial dysfunction, chronic inflammation, tumor initiation, metastasis, angiogenesis, and therapeutic resistance. Moreover, FOSL1-driven transcriptional networks show mechanistic overlap between IBD-associated colorectal cancer (CRC) and other inflammation-linked gastrointestinal cancers, such as pancreatic ductal adenocarcinoma (PDAC). In this review, we summarize current knowledge on the regulation and function of FOSL1 in intestinal inflammation and IBD-associated cancers, highlight its context-dependent roles in epithelial and immune compartments, and discuss emerging therapeutic strategies aimed at indirectly targeting FOSL1 signaling pathways.